Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study

for the FUTURE-1 Study Group

Research output: Contribution to journalArticle

37 Scopus citations

Fingerprint Dive into the research topics of 'Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study'. Together they form a unique fingerprint.

Medicine & Life Sciences